United Kingdom

People: Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

13 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Moskal, Joseph 

Dr. Joseph R. Moskal Ph.D. is Chief Scientific Officer of the company. Dr. Moskal has served as our Chief Scientific Officer since July 2015. He founded Naurex in September 2006 and served as its chief scientific officer until the company was acquired by Allergan plc in July 2015. He is also a professor of biomedical engineering at Northwestern University and director of the university's Falk Center for Molecular Therapeutics. Dr. Moskal previously served as assistant professor and director of the neurosurgery laboratories at the Albert Einstein College of Medicine. Earlier, he was a staff fellow at the National Institutes of Health. Dr. Moskal is well known for his research on the NMDAr. He received a B.S. and a Ph.D. from the University of Notre Dame.

Basic Compensation

Total Annual Compensation, USD 464,467
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 33,391
Fiscal Year Total, USD 497,858

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --